文献速递治疗药物监测与药物基因组学药物相互作用特殊人群用药

基于真实世界数据的机器学习模型预测喹硫平血药浓度

A machine learning model for predicting blood concentration of quetiapine in patients with schizophrenia and depression based on real-world data.
PubMed 文献 · Br J Clin Pharmacol · 2023-05-07

本研究基于河北医科大学第一医院650例喹硫平治疗药物监测数据,采用机器学习方法建立精神分裂症和抑郁症患者喹硫平血药浓度预测模型。筛选出日剂量、精神疾病类型、性别和CYP2D6竞争性底物四个变量,CatBoost算法预测性能最佳,平均R²为0.63。

要点

  • 日剂量、疾病类型、性别和CYP2D6竞争性底物是喹硫平血药浓度的预测变量
  • CatBoost模型预测值在治疗参考范围200-750 ng/mL内的平均准确率为73.54%
  • 模型预测值在实测值±30%范围内的平均准确率为49.46%

核心结论

  • CatBoost机器学习模型可基于真实世界数据预测精神分裂症和抑郁症患者喹硫平血药浓度,辅助临床方案决策。

研究设计与样本

  • 采用单因素分析和序列前向选择筛选变量,经10折交叉验证从9种算法中选择最优模型,并用SHAP解释模型。

主要发现

  • 单因素分析(P < .05)和SFS筛选出日剂量、精神疾病类型、性别和CYP2D6竞争性底物四个变量。
  • CatBoost算法预测性能最佳,平均(SD)R² = 0.63 ± 0.02,RMSE = 137.39 ± 10.56,MAE = 103.24 ± 7.23。
  • 预测TDM值在实测值±30%范围内的平均(SD)准确率为49.46 ± 3.00%,在推荐治疗范围(200-750 ng mL-1)内的平均(SD)准确率为73.54 ± 8.3%。
  • 与既往PBPK模型相比,CatBoost模型在实测值±100%范围内的准确率略高。

关键数值与推荐

  • 喹硫平推荐治疗参考范围为200-750 ng mL-1。
  • 模型预测值在实测值±30%范围内的平均准确率为49.46 ± 3.00%。
  • 模型预测值在治疗参考范围200-750 ng mL-1内的平均准确率为73.54 ± 8.3%。

临床怎么用

  • 对于精神分裂症或抑郁症患者,可依据日剂量、疾病类型、性别及合并使用CYP2D6竞争性底物情况,用CatBoost模型预估喹硫平血药浓度。
  • 模型预测值可作为TDM的补充参考,尤其关注预测值是否落在200-750 ng mL-1治疗参考范围内。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: This study aimed to establish a prediction model of quetiapine concentration in patients with schizophrenia and depression, based on real-world data via machine learning techniques to assist clinical regimen decisions. METHODS: A total of 650 cases of quetiapine therapeutic drug monitoring (TDM) data from 483 patients at the First Hospital of Hebei Medical University from 1 November 2019 to 31 August 2022 were included in the study. Univariate analysis and sequential forward selection (SFS) were implemented to screen the important variables influencing quetiapine TDM. After 10-fold cross validation, the algorithm with the optimal model performance was selected for predicting quetiapine TDM among nine models. SHapley Additive exPlanation was applied for model interpretation. RESULTS: Four variables (daily dose of quetiapine, type of mental illness, sex and CYP2D6 competitive substrates) were selected through univariate analysis (P < .05) and SFS to establish the models. The CatBoost algorithm with the best predictive ability (mean [SD] R2 = 0.63 ± 0.02, RMSE = 137.39 ± 10.56, MAE = 103.24 ± 7.23) was chosen for predicting quetiapine TDM among nine models. The mean (SD) accuracy of the predicted TDM within ±30% of the actual TDM was 49.46 ± 3.00%, and that of the recommended therapeutic range (200-750 ng mL-1 ) was 73.54 ± 8.3%. Compared with the PBPK model in a previous study, the CatBoost model shows slightly higher accuracy within ±100% of the actual value. CONCLUSIONS: This work is the first real-world study to predict the blood concentration of quetiapine in patients with schizophrenia and depression using artificial intelligent techniques, which is of significance and value for clinical medication guidance.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Hao Y, Zhang J, Yang L, et al. A machine learning model for predicting blood concentration of quetiapine in patients with schizophrenia and depression based on real-world data. Br J Clin Pharmacol. 2023. PMID: 37005382. doi:10.1111/bcp.15734

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。